Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Gaboxadol with Placebo (2 arms). Primary endpoint: Long-term safety and tolerability. Started Jun 2003; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Gaboxadol
Patients receiving gaboxadol monotherapy.
Placebo
Patients receiving matching placebo.
03
Who it enrols
Patients with Primary insomnia
04
Endpoints
Primary
Long-term safety and tolerability
Beyond the preview
Go deeper on NCT00209963.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209963.